BMRN Logo

BioMarin Pharmaceutical Inc. (BMRN) 

NASDAQ
Market Cap
$12.72B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
580 of 966
Rank in Industry
315 of 554

Largest Insider Buys in Sector

BMRN Stock Price History Chart

BMRN Stock Performance

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Insider Activity of BioMarin Pharmaceutical Inc.

Over the last 12 months, insiders at BioMarin Pharmaceutical Inc. have bought $0 and sold $24.17M worth of BioMarin Pharmaceutical Inc. stock.

On average, over the past 5 years, insiders at BioMarin Pharmaceutical Inc. have bought $658,092 and sold $25.48M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,625 shares for transaction amount of $314,469 was made by Alles Mark J (director) on 2022‑10‑31.

List of Insider Buy and Sell Transactions, BioMarin Pharmaceutical Inc.

2024-11-12SaleEVP, Chief Technical Officer
5,278
0.0028%
$66.37$350,324-1.61%
2024-08-13SaleGVP, Chief Accounting Officer
714
0.0004%
$90.00$64,2600.00%
2024-05-30SaleEVP, Chief Financial Officer
5,000
0.0027%
$75.19$375,950+6.19%
2024-05-28SaleEVP, Chief Legal Officer
40,850
0.0215%
$74.51$3.04M+2.66%
2024-05-10Saledirector
20,000
0.0105%
$81.14$1.62M-4.92%
2024-05-09Saledirector
20,000
0.0105%
$81.62$1.63M-5.68%
2024-05-02SaleEVP, Chief Commercial Officer
5,000
0.0026%
$82.91$414,550-6.49%
2024-05-02SaleEVP, Chief Legal Officer
1,850
0.001%
$85.01$157,269-6.49%
2024-04-12Saledirector
20,000
0.0104%
$91.26$1.83M-12.46%
2024-04-11Saledirector
20,000
0.0105%
$90.99$1.82M-11.70%
2024-04-10SaleGVP, Chief Accounting Officer
2,286
0.0012%
$90.00$205,740-10.43%
2024-03-28SaleEVP, Chief Legal Officer
24,602
0.0132%
$88.34$2.17M-6.37%
2024-03-06Saledirector
1,000
0.0005%
$86.71$86,713-3.96%
2024-03-05Saledirector
1,000
0.0005%
$85.51$85,510-3.15%
2024-03-05SalePresident, Worldwide R&D
35,341
0.0186%
$85.18$3.01M-3.15%
2024-03-05SaleEVP, Chief Commercial Officer
4,000
0.0021%
$87.07$348,280-3.15%
2024-02-27Saledirector
1,000
0.0005%
$90.35$90,350-7.62%
2024-02-09Saledirector
15,000
0.0078%
$88.28$1.32M-4.95%
2024-02-08Saledirector
15,000
0.0079%
$89.77$1.35M-4.61%
2024-01-10Saledirector
10,000
0.0054%
$96.38$963,800-11.40%

Insider Historical Profitability

19.67%
BIENAIME JEAN JACQUESdirector
474994
0.2492%
$66.7226321+29.88%
FUCHS HENRY JPresident, Worldwide R&D
212117
0.1113%
$66.72072
Mueller BrianEVP, Chief Financial Officer
72159
0.0379%
$66.72232+36.78%
Guyer Charles GregEVP, Chief Technical Officer
68909
0.0362%
$66.7203
Ajer Jeffrey RobertEVP, Chief Commercial Officer
66767
0.035%
$66.72066
Davis George EricEVP, Chief Legal Officer
56157
0.0295%
$66.72473+5.04%
Burkhart ErinGVP, Chief Accounting Officer
14449
0.0076%
$66.7202
WILLIAMS GWYNNdirector
812565
0.4264%
$66.7208
STARR CHRISTOPHER MSVP, Chief Scientific Officer
295176
0.1549%
$66.7207
MEIER RICHARD A
104032
0.0546%
$66.7249+42.46%
PRICE FREDRIC DChief Executive Officer
79285
0.0416%
$66.7210<0.0001%
BAFFI ROBERTEVP, Technical Operations
71882
0.0377%
$66.72830+11.93%
ASELAGE STEVEEVP, Chief Business Officer
59030
0.031%
$66.72725+6.62%
SPIEGELMAN DANIEL KEVP, Chief Financial Officer
47510
0.0249%
$66.72033
GREY MICHAEL Gdirector
42840
0.0225%
$66.7207
HERON ELAINE Jdirector
41685
0.0219%
$66.7207
Cooper Jeffrey HSVP, Chief Financial Officer
41089
0.0216%
$66.72426<0.0001%
KAKKIS EMIL DChief Medical Officer
39621
0.0208%
$66.72614+3.16%
KLEIN JOSEPH IIIdirector
35000
0.0184%
$66.7234+42.82%
PYOTT DAVID E Idirector
30740
0.0161%
$66.7210+0.47%
LAPALME PIERREdirector
30150
0.0158%
$66.7246+9.26%
LAWLIS V BRYANdirector
28950
0.0152%
$66.72028
Slamon Dennisdirector
21639
0.0114%
$66.7201
LEWIS ALANdirector
21160
0.0111%
$66.7208
Wood MarkVP, Human Resources
20277
0.0106%
$66.72189+66.1%
Dere Willard Hdirector
13290
0.007%
$66.7201
Alles Mark Jdirector
10905
0.0057%
$66.7210+6.56%
Swiedler Stuart JSVP, Clinical Affairs
10000
0.0052%
$66.72011
SAGER ERICHdirector
3309
0.0017%
$66.7206
URQUHART JOHNdirector
0
0%
$66.7201

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
PRIMECAP Management Co$1.63B9.8618.71M+1.63%+$26.16M1.2
The Vanguard Group$1.58B9.5418.12M+0.37%+$5.86M0.03
BlackRock$1.26B7.6314.48M-1.38%-$17.72M0.03
Dodge & Cox$1.22B7.3713.99M<0.01%-$97,820.800.71
State Street$602.23M3.636.9M+2.45%+$14.38M0.03
Capital Research Global Investors$569.51M3.436.52M-39.48%-$371.54M0.13
Viking Global Investors$560.4M3.386.42M+31.23%+$133.35M0.2
Ameriprise Financial$471.95M2.855.4M-0.29%-$1.38M0.13
Barclays$458.93M2.775.25M-0.65%-$3M0.21
UBS$441.63M2.665.06M+5,369.26%+$433.55M0.13
Avoro Capital Advisors Llc$381.24M2.34.37M+1.51%+$5.68M4.57
Elliott Investment Management L P$305.72M1.843.5M+16.66%+$43.67M3.21
Geode Capital Management$260.44M1.572.99M+3.98%+$9.97M0.02
Bank of America$243.65M1.472.79M+18.26%+$37.63M0.02
BNY Mellon$230.36M1.392.64M+3.02%+$6.75M0.04
JPMorgan Chase$211.54M1.282.42M-1.05%-$2.25M0.02
Deutsche Bank$204.31M1.232.34M-31.24%-$92.84M0.09
Millennium Management LLC$198.89M1.22.28M+94.91%+$96.84M0.13
Citadel Advisors LLC$172.55M1.041.98M+456.58%+$141.54M0.1
Nomura Holdings$130.25M0.791.49M-30.08%-$56.04M1.14
Legal & General$120.36M0.731.38M-0.89%-$1.08M0.03
Point72 Asset Management$117.54M0.711.35M+195.57%+$77.77M0.17
Charles Schwab$117.15M0.711.34M-2.73%-$3.28M0.03
OrbiMed$111.66M0.671.28M-18.64%-$25.58M0.86
Fort Washington Investment Advisors Inc Oh$101.95M0.621.17M+0.14%+$145,508.440.67
Manning Napier Group Llc$100.77M0.611.15M+0.76%+$757,393.071.26
Palo Alto Investors Lp$99.09M0.61.13M-24.4%-$31.98M11.18
CalPERS$96.51M0.581.11M-3.88%-$3.9M0.07
T. Rowe Price$96.28M0.581.1M-31.36%-$43.99M0.01
Northern Trust$94.16M0.571.08M-6.32%-$6.35M0.02
Morgan Stanley$88.24M0.531.01M+7.43%+$6.1M0.01
Parnassus Investments Ca$76.25M0.46873,001-52.79%-$85.27M0.16
Dnb Asset Management As$75.74M0.46867,187+16.32%+$10.63M0.4
Squarepoint Ops LLC$75.22M0.45861,217+209%+$50.88M0.27
Nuveen$74.62M0.45854,392+39.74%+$21.22M0.02
Ubs Asset Management Americas Inc$65.05M0.39744,801-0.25%-$160,618.260.02
Dimensional Fund Advisors$65.02M0.39744,504+5.61%+$3.45M0.02
HERITAGE ASSET MANAGEMENT INC$62.06M0.38712,529+63.32%+$24.06M0.32
Two Sigma$61.18M0.37700,499+69.22%+$25.03M0.09
Janus Henderson$60.83M0.37696,518-75.04%-$182.88M0.03
Goldman Sachs$60.55M0.37693,224-23.64%-$18.74M0.01
American Century Investments$60.61M0.37693,912+0.94%+$564,915.120.04
Scout Investments$58.87M0.36675,868-14.62%-$10.08M1.48
Susquehanna International Group$59.1M0.36676,686+160.71%+$36.43M0.06
Fiera Capital$53.8M0.32615,944-5.94%-$3.4M0.16
Swiss National Bank$49.28M0.3564,200-4.11%-$2.11M0.03
Northwestern Mutual Wealth Management Co$49.12M0.3562,376+8.08%+$3.67M0.05
KeyBank$48.95M0.3560,479-9.74%-$5.28M0.2
Two Sigma Advisers LP$47.6M0.29545,014+62.59%+$18.32M0.08
Renaissance Technologies$47.34M0.29542,071+40.19%+$13.57M0.08
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.